Medical Research and Clinical Trials

Groundbreaking Oklahoma Research Unveils How Aggressive Breast Cancer Hijacks Immune System to Fuel Growth

• Medical Research and Clinical Trials

Groundbreaking Oklahoma Research Unveils How Aggressive Breast Cancer Hijacks Immune System to Fuel Growth

Nana Muazin October 8, 2026

Oklahoma City, OK – In a significant leap forward for cancer research, scientists at the University of...

Read More Read more about Groundbreaking Oklahoma Research Unveils How Aggressive Breast Cancer Hijacks Immune System to Fuel Growth

ArriVent’s Firmonertinib Falls Short in Key NSCLC Trial, Sending Stock Plummeting Amidst Competitive Landscape

• Medical Research and Clinical Trials

ArriVent’s Firmonertinib Falls Short in Key NSCLC Trial, Sending Stock Plummeting Amidst Competitive Landscape

Basiran October 8, 2026

Disappointing Phase III results for ArriVent BioPharma’s lead candidate, firmonertinib, in the treatment of non-small cell lung...

Read More Read more about ArriVent’s Firmonertinib Falls Short in Key NSCLC Trial, Sending Stock Plummeting Amidst Competitive Landscape

Unveiling a Cunning Cancer Strategy: How Triple-Negative Breast Cancer Recruits Nerves for Growth and Survival

• Medical Research and Clinical Trials

Unveiling a Cunning Cancer Strategy: How Triple-Negative Breast Cancer Recruits Nerves for Growth and Survival

Iffa Jayyana October 7, 2026

OKLAHOMA CITY, OK – In a significant breakthrough that redefines our understanding of aggressive cancers, new research...

Read More Read more about Unveiling a Cunning Cancer Strategy: How Triple-Negative Breast Cancer Recruits Nerves for Growth and Survival

ArriVent’s Firmonertinib Fails to Meet Primary Endpoint in NSCLC Trial, Stock Plummets Amidst Competitive Landscape

• Medical Research and Clinical Trials

ArriVent’s Firmonertinib Fails to Meet Primary Endpoint in NSCLC Trial, Stock Plummets Amidst Competitive Landscape

Muslim October 7, 2026

A significant setback for ArriVent BioPharma has sent its stock price into a tailspin, following the disappointing...

Read More Read more about ArriVent’s Firmonertinib Fails to Meet Primary Endpoint in NSCLC Trial, Stock Plummets Amidst Competitive Landscape

Unveiling a Devious Strategy: How Aggressive Breast Cancer Hijacks the Immune System to Fuel Growth

• Medical Research and Clinical Trials

Unveiling a Devious Strategy: How Aggressive Breast Cancer Hijacks the Immune System to Fuel Growth

Sagoh October 7, 2026

NORMAN, OKLAHOMA – In a significant breakthrough that could redefine future cancer treatments, new research from the...

Read More Read more about Unveiling a Devious Strategy: How Aggressive Breast Cancer Hijacks the Immune System to Fuel Growth

ArriVent’s Promising NSCLC Candidate Falters in Phase III Trial, Stock Plummets Amidst Competitive Landscape

• Medical Research and Clinical Trials

ArriVent’s Promising NSCLC Candidate Falters in Phase III Trial, Stock Plummets Amidst Competitive Landscape

Pevita Pearce October 7, 2026

The oncology landscape for non-small cell lung cancer (NSCLC) with specific EGFR mutations has taken a significant...

Read More Read more about ArriVent’s Promising NSCLC Candidate Falters in Phase III Trial, Stock Plummets Amidst Competitive Landscape

A Neural Invasion: Oklahoma Researchers Uncover How Aggressive Breast Cancer Hijacks the Immune System to Fuel Growth

• Medical Research and Clinical Trials

A Neural Invasion: Oklahoma Researchers Uncover How Aggressive Breast Cancer Hijacks the Immune System to Fuel Growth

Ali Ikhwan October 7, 2026

NORMAN, OK – In a groundbreaking discovery that redefines our understanding of aggressive breast cancer, scientists at...

Read More Read more about A Neural Invasion: Oklahoma Researchers Uncover How Aggressive Breast Cancer Hijacks the Immune System to Fuel Growth

Zipalertinib Combination Shows Significant Progression-Free Survival Gains in Previously Untreated Advanced NSCLC, Taiho Oncology CMO Reveals

• Medical Research and Clinical Trials

Zipalertinib Combination Shows Significant Progression-Free Survival Gains in Previously Untreated Advanced NSCLC, Taiho Oncology CMO Reveals

Nana Muazin October 7, 2026

Taiho Oncology’s Chief Medical Officer, Dr. Harold Keer, has provided crucial insights into the groundbreaking results of...

Read More Read more about Zipalertinib Combination Shows Significant Progression-Free Survival Gains in Previously Untreated Advanced NSCLC, Taiho Oncology CMO Reveals

Unlocking the Enigma of Metastasis: Scientists Pinpoint Key Factor Driving Colorectal Cancer Spread to the Liver

• Medical Research and Clinical Trials

Unlocking the Enigma of Metastasis: Scientists Pinpoint Key Factor Driving Colorectal Cancer Spread to the Liver

Asro October 7, 2026

NEW YORK, NY & CAMBRIDGE, MA – June 22, 2024 – In a significant breakthrough that could...

Read More Read more about Unlocking the Enigma of Metastasis: Scientists Pinpoint Key Factor Driving Colorectal Cancer Spread to the Liver

Unveiling Cancer’s Deceptive Alliance: OU Research Exposes How Aggressive Breast Cancer Hijacks the Immune System to Recruit Nerves

• Medical Research and Clinical Trials

Unveiling Cancer’s Deceptive Alliance: OU Research Exposes How Aggressive Breast Cancer Hijacks the Immune System to Recruit Nerves

Nila Kartika Wati October 7, 2026

Oklahoma City, OK – In a significant stride toward understanding and potentially conquering one of the most...

Read More Read more about Unveiling Cancer’s Deceptive Alliance: OU Research Exposes How Aggressive Breast Cancer Hijacks the Immune System to Recruit Nerves